<code id='6A91B764FA'></code><style id='6A91B764FA'></style>
      • <acronym id='6A91B764FA'></acronym>
      <center id='6A91B764FA'><center id='6A91B764FA'><tfoot id='6A91B764FA'></tfoot></center><abbr id='6A91B764FA'><dir id='6A91B764FA'><tfoot id='6A91B764FA'></tfoot><noframes id='6A91B764FA'>
      • <optgroup id='6A91B764FA'><strike id='6A91B764FA'><sup id='6A91B764FA'></sup></strike><code id='6A91B764FA'></code></optgroup>
        5. <b id='6A91B764FA'><label id='6A91B764FA'><select id='6A91B764FA'><dt id='6A91B764FA'><span id='6A91B764FA'></span></dt></select></label></b><u id='6A91B764FA'></u>
          <i id='6A91B764FA'><strike id='6A91B764FA'><tt id='6A91B764FA'><pre id='6A91B764FA'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-09-30 22:24:16 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：focus   
                                        
                                      
                                      Page View：3982
                                  
                                    
          
                                   
          Rachel Haurwitz of Caribou Biosciences
          Rachel Haurwitz, CEO of Caribou Biosciences.																									Elizabeth D. Herman for STAT
          Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.
          In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.
          advertisement
          The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Why more medical students aren't specializing in primary care
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles